Beneficial cardiometabolic actions of telmisartan plus amlodipine therapy in elderly patients with poorly controlled hypertension

Clinical Cardiology

Volumn 34, Issue 4, 2011, Pages 261-265

  Bekki, Hisatoshi ^a   Yamamoto, Kiichiro ^a   Sone, Masayoshi ^a   Homma, Tomoki ^a   Nakata, Masashi ^a   Nohara, Masatoshi ^a   Fukami, Kei ^b   Okuda, Seiya ^b   Yamagishi, Sho Ichi ^b  

^a ABC Trial Group   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; AMLODIPINE; CANDESARTAN; CREATININE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TELMISARTAN; TRIACYLGLYCEROL; VALSARTAN;

AGED; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; FEMALE; GERIATRIC PATIENT; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; MALE; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPONECTIN; AGE FACTORS; AGED; AGED, 80 AND OVER; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; JAPAN; MALE; PROSPECTIVE STUDIES; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION; VALINE;

EID: 79953721690     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20855     Document Type: Article

References (31)

1. US Census Bureau. Estimated world population figures 2020. Available at: http://www.census.gov/ipc/www/idb/tables.html. Accessed April 13, 2009.
2. Ogihara T, Kikuchi K, Matsuoka H, et al; Japanese Society of Hypertension Committee. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Chapter 8. Hypertension in the elderly. Hypertension Res. 2009;32:57-62.
3. Kostis JB. Antihypertensive therapy with CCB/ARB combination in older individuals: focus on amlodipine/valsartan combination. Am J Ther. 2010;17:188-196.
4. Turnbull F. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527-1535. (Pubitemid 37410190)
5. Arima H, Tanizaki Y, Kiyohara Y, et al. Validity of the JNC VI recommendations for themanagement of hypertension in a general population of Japanese elderly: the Hisayama study. Arch Intern Med. 2003;163:361-366. (Pubitemid 36183866)
6. Murakami Y, Hozawa A, Okamura T, et al; Evidence for Cardiovascular Prevention From Observational Cohorts in Japan Research Group (EPOCH-JAPAN). Relation of blood pressure and all-cause mortality in 180,000 Japanese participants: pooled analysis of 13 cohort studies. Hypertension. 2008;51:1483-1491.
7. Jamerson K,Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417-2428.
8. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559. (Pubitemid 351522739)
9. McDowell SE, Coleman JJ, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ. 2006;332:1177-1181.
10. Ogihara T, Kikuchi K, Matsuoka H, et al; Japanese Society of Hypertension Committee. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Chapter 2.Measurement and clinical evaluation of blood pressure. Hypertens Res. 2009;32:11-23.
11. Bekki H, Yamamoto K, Sone M, et al. Efficacy of combination therapy with telmisartan plus amlodipine in patients with poorly controlled hypertension. Oxid Med Cell Longev. In press.
12. Tahara N, Imaizumi T, Takeuchi M, et al. Insulin resistance is an independent correlate of high serum levels of advanced glycation end products (AGEs) and low testosterone in non-diabetic men. Oxid Med Cell Longev. In press.
13. Matsuo S, Imai E, Horio M, et al; Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982-992.
14. Higaki J, Baba S, Katsuya T, et al. Deletion allele of angiotensin-converting enzyme gene increases risk of essential hypertension in Japanese men: the Suita Study. Circulation. 2000;101:2060-2065. (Pubitemid 30233169)
15. Yamagishi S, Nakamura K, Matsui T. Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-γ (PPAR-γ)-modulating activity for the treatment of cardiometabolic disorders. Curr Mol Med. 2007;7:463-469. (Pubitemid 47244891)
16. Lewis EJ, Hunsicker LG, Clarke WR, et al; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
17. Kamoi K, Miyakoshi M, Soda S, et al. Usefulness of home blood pressure measurement in the morning in type 2 diabetic patients. Diabetes Care. 2002;25:2218-2223. (Pubitemid 41071031)
18. Ohkubo T, Imai Y, Tsuji I, et al.Homeblood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: a population-based observation in Ohasama, Japan. J Hypertens. 1998;16:971-975. (Pubitemid 28367951)
19. Tsunoda S, Kawano Y, Horio T, et al. Relationship between home blood pressure and longitudinal changes in target organ damage in treated hypertensive patients. Hypertens Res. 2002;25:167-173. (Pubitemid 34464444)
20. Kelly-Hayes M, Wolf PA, Kase CS, et al. Temporal patterns of stroke onset: the Framingham Study. Stroke. 1995;26: 1343-1347.
21. Goldberg RJ, Brady P, Muller JE, et al. Time of onset of symptoms of acute myocardial infarction. Am J Cardiol. 1990;66:140-144. (Pubitemid 20235718)
22. Weber MA. The 24-hour blood pressure pattern: does it have implications for morbidity and mortality? Am J Cardiol. 2002;89:27A-33A.
23. Kario K, Pickering TG, Umeda Y, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation. 2003;107:1401-1406. (Pubitemid 36350739)
24. Nishimura T, Hashimoto J, Ohkubo T, et al. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements. Clin Exp Hypertens. 2005;27:477-489. (Pubitemid 41170279)
25. Kakuta H, Sudoh K, Sasamata M, et al. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res. 2005;25:414-416.
26. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet. 2000;355:637-645. (Pubitemid 30099477)
27. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension. 2004;43:993-1002. (Pubitemid 38579904)
28. Gurevich-Panigrahi T, Panigrahi S, Wiechec E, et al. Obesity: pathophysiology and clinical management. Curr Med Chem. 2009;16:506-521.
29. Araki K, Masaki T, Katsuragi I, et al. Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice. Hypertension. 2006;48:51-57. (Pubitemid 44297524)
30. Miura Y, Yamamoto N, Tsunekawa S, et al. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences. Diabetes Care. 2005;28:757-758. (Pubitemid 40315351)
31. Gustafson B. Adipose tissue, inflammation and atherosclerosis. J Atheroscler Thromb 2010;17:332-341.